Compare MYO & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYO | CELU |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.9M | 34.5M |
| IPO Year | 2017 | N/A |
| Metric | MYO | CELU |
|---|---|---|
| Price | $0.68 | $1.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $7.67 | $6.00 |
| AVG Volume (30 Days) | ★ 367.8K | 28.0K |
| Earning Date | 06-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,000,000,000.00 | N/A |
| Revenue This Year | $24.07 | N/A |
| Revenue Next Year | $17.48 | $76.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 40814.79 | N/A |
| 52 Week Low | $0.64 | $1.01 |
| 52 Week High | $6.27 | $4.35 |
| Indicator | MYO | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 38.18 | 57.21 |
| Support Level | $0.64 | $1.21 |
| Resistance Level | $1.03 | $1.51 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 23.90 | 69.75 |
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.